Loading patent…
AssigneeDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsMathias Heikenwälder, Lars Zender, Achim Weber
Estimating the term…
The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.
A method for the treatment of non-alcoholic steatohepatitis (NASH), wherein said method comprises administering, to a subject in need of such treatment, an inhibitor of Gp1b, wherein the inhibitor is an antigen-binding fragment of an anti-Gp1b antibody that specifically and selectively binds to a Gp1b protein and inhibits its function.
Dependencies are inferred from the claim text.